Search Results for: Avandia

Featured Stories

Transvaginal Mesh a Nightmare for Thousands of Women

Thousands of women who have received transvaginal mesh surgical implants to treat stress urinary incontinence (SUI) and pelvic organ prolapse (POP) are now living a nightmare, thanks to debilitating pain, bleeding, infection and other serious complications. According to the Sun-Sentinel, many of the women injured by transvaginal mesh claim ...

Read More

Majority of Metal-on-Metal Hip Implant Failures Occur within Two Years, Study Finds

A newly published metal-on-metal hip replacement study is reporting that the majority of failures occur early, within two years of surgery. The study, published in the journal Orthopedics, is just the latest to indicate that close follow-up of metal-on-metal hip implant patients is warranted.

Read More

Federal DePuy ASR Hip Implant Trials Likely to Start This Year

It looks as though the first trials in the DePuy ASR hip implant multidistrict litigation could begin sometime later this year. According to a report from Bloomberg News, during a status conference held yesterday in Florida, attorneys for both plaintiffs and the defense told U.S. District Judge David Katz that ...

Read More

Lawsuits over DePuy ASR Metal-on-Metal Hip Implants Continue to Mount

DePuy Orthopaedics and its parent, Johnson & Johnson, continue to be hit with lawsuits over recalled metal-on-metal DePuy ASR hip implants. Just yesterday, the national law firm of Parker Waichman LLP announced it had filed yet another DePuy ASR hip implant lawsuit, this time on behalf of a Virginia resident ...

Read More

Bisphosphonate Study Confirms Atypical Thigh Fracture Risk

New research has confirmed the link between bisphoshonates, such as Fosamax, and atypical femur fractures, a type of thigh fracture that occurs spontaneously, without any major leg injury. The study, published in the Archives of Internal Medicine, also found that the risk of atypical thigh fractures increases the longer a ...

Read More

Study Linking Z-Pak to Increased Death Risk Being Reviewed by FDA

The U.S. Food & Drug Administration (FDA) is reviewing a new study that reported an increased risk of sudden, heart-related deaths among people using the antibiotic Zithromax (azithromycin), known popularly as Z-Pak. In a statement issued late yesterday, the FDA said patients being treated with Zithromax should not stop taking ...

Read More

FDA Advisors Set to Examine Metal-on-Metal Hip Implant Safety Concerns

Thousands of people with metal-on-metal hip implant devices could soon get some answers from the U.S. Food & Drug Administration (FDA) about the dangers they face. Tomorrow, the agency will convene a panel of outside medical experts to examine the safety record of metal-on-metal hip replacements, and recommend the ...

Read More

Pradaxa Associated with more Complications than Warfarin, According to Early Study Findings

Early results from the largest study to date to compare Pradaxa and warfarin indicate that in a real-world setting, Pradaxa causes more complications than decades-old warfarin. The preliminary study results were announced last week, during the 2012 Thrombosis and Hemostasis Summit of North America.

Read More

Death in Those Taking Bactrim with ACE Inhibitors or ARBs

Sudden Death in Those Taking Bactrim Along with ACE Inhibitors or ARBs

Association between sudden death in those given Bactrim while already taking renin-angiotensin system blockers angiotensin receptor blockers (ARBs), heart medications.

Read More

Glaxo Agrees to $229 Million Avandia Settlement with Eight States

glaxo_avandia_settlement

In response to lawsuits brought by eight U.S. states, drug maker, GlaxoSmithKline, has agreed to pay hundreds of millions of dollars to settle actions over diabetes medication, Avandia (rosiglitazone). The drug maker announced it would pay $229 million and, in … Continue reading

Posted in Avandia, Pharmaceuticals |

FDA Recommends Easing Avandia Restrictions

FDA_Avandia_Restrictions

A vote at the conclusion of a two-day meeting of United States health advisors ended with a recommendation to ease current market restrictions on Type 2 diabetes drug, Avandia, which is marketed by GlaxoSmithKline. The U.S. Food and Drug Administration … Continue reading

Posted in Avandia, Legal News, Pharmaceuticals |

FDA Reconsidering its Stance on Avandia

FDA-Avandia-Restrictions

In an unprecedented move, the U.S. Food and Drug Administration is reopening the matter involving Type 2 diabetes drug, Avandia, which is marketed by GlaxoSmithKline. Avandia belongs to a class of diabetes drugs called thiazolidinediones that lower blood sugar by … Continue reading

Posted in Avandia, Pharmaceuticals |

Glaxo to Resolve Avandia, Paxil, Wellbutrin Fraud Charges with Justice Department for Record-Breaking $3 Billion

The U.S. Justice Department has announced another record-breaking settlement with a pharmaceutical company accused of illegally marketing some of its drugs.  According to a statement issued by the Department late yesterday, GlaxoSmithKline will pay $3 billion to settle charges involving … Continue reading

Posted in Avandia, Pharmaceuticals, SSRI Antidepressants | Tagged |

Actos, Avandia May Up Risk for Diabetic Macular Edema

Actos, Avandia May Up Risk for Diabetic Macular Edema

A newly published study is raising concerns that patients who take Actos or Avandia may face an increased risk of developing diabetic macular edema, an eye disorder that can result in vision loss. The study, published in the Archives of … Continue reading

Posted in Actos, Pharmaceuticals | Tagged |

Actos Whistleblower Lawsuit Questions Avandia Researcher’s Financial Ties to Takeda

A prominent researcher has been implicated in an alleged cover-up of Actos side effects, according to a report from TheHeart.org. An Actos whistleblower lawsuit unsealed earlier this year has alleged financial connections between the Cleveland Clinic’s Dr Steven Nissen and … Continue reading

Posted in Actos, Pharmaceuticals | Tagged |

Mediation Leads To Settlement Of 25,000 Avandia Lawsuits

Multidistrict litigation mediation has led to the settlement of about 25,000 Avandia lawsuits. Avandia was GlaskoSmithKline’s once-blockbuster type 2 diabetes drug. This November, U.S. District Judge Cynthia Rufe appointed a mediator to preside over settlement negotiation for the cases, setting … Continue reading

Posted in Avandia, Pharmaceuticals |

Avandia Mediation Nets Settlement for 20,000 Heart Attack Lawsuits

Pharmaceutical giant GlaxoSmithKline has agreed to settle about 20,000 heart attack lawsuits brought by former users of its Type 2 diabetes medication Avandia. The lawsuits are among thousands more which claim GlaxoSmithKline (GSK) hid data showing the leading diabetes drug … Continue reading

Posted in Avandia, Pharmaceuticals |

Glaxo May Mediate More Avandia Settlements

Last week, we wrote that GlaxoSmithKline Plc agreed to pay $3 billion to resolve federal investigations into how it marketed some of its drugs, including its controversial type 2 diabetes drug, Avandia. Now, a judge is urging the drug maker … Continue reading

Posted in Avandia, Pharmaceuticals |

Glaxo to Settle Avandia, Other Federal Drug Marketing Investigations

GlaxoSmithKline has agreed to pay $3 billion to resolve federal investigations into the marketing of some of its drugs, including the controversial type 2 diabetes drug, < "http://www.yourlawyer.com/topics/overview/avandia">Avandia. According to a report from Bloomberg News, the agreement with the U.S. … Continue reading

Posted in Avandia, Pharmaceuticals |

© 2005-2020 Parker Waichman LLP ®. All Rights Reserved.